Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients.

Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP.

Aliment Pharmacol Ther. 2010 Nov;32(10):1240-8. doi: 10.1111/j.1365-2036.2010.04465.x. Epub 2010 Sep 23.

3.

Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.

Laine L, Curtis SP, Langman M, Jensen DM, Cryer B, Kaur A, Cannon CP.

Gastroenterology. 2008 Nov;135(5):1517-25. doi: 10.1053/j.gastro.2008.07.067. Epub 2008 Aug 3.

PMID:
18823986
4.

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.

Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS.

JAMA. 2000 Sep 13;284(10):1247-55.

PMID:
10979111
5.

Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.

Hsiang KW, Chen TS, Lin HY, Luo JC, Lu CL, Lin HC, Lee KC, Chang FY, Lee SD.

Clin Ther. 2010 Jul;32(7):1294-303. doi: 10.1016/j.clinthera.2010.07.005.

PMID:
20678677
7.

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.

Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L; MEDAL Steering Committee..

Lancet. 2006 Nov 18;368(9549):1771-81.

PMID:
17113426
8.

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.

Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.

Am J Gastroenterol. 2003 Aug;98(8):1725-33.

PMID:
12907325
9.

Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis.

Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, Reicin A.

Gastroenterology. 2002 Oct;123(4):1006-12.

PMID:
12360461
10.

The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.

Arber N, Lieberman D, Wang TC, Zhang R, Sands GH, Bertagnolli MM, Hawk ET, Eagle C, Coindreau J, Zauber A, Lanas A, Levin B.

Clin Ther. 2012 Mar;34(3):569-79. doi: 10.1016/j.clinthera.2012.02.001. Epub 2012 Mar 2.

PMID:
22386831
11.

Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.

Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T.

J Med Assoc Thai. 2009 Dec;92 Suppl 6:S19-26.

PMID:
20128070
12.

Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).

Krueger K, Lino L, Dore R, Radominski S, Zhang Y, Kaur A, Simpson R, Curtis S.

Ann Rheum Dis. 2008 Mar;67(3):315-22. Epub 2007 Oct 27. Erratum in: Ann Rheum Dis.2008 May;67(5):732.

PMID:
17965424
13.

Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.

[No authors listed]

Prescrire Int. 2007 Dec;16(92):223-7.

PMID:
18084859
14.
15.

Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.

Baraf HS, Fuentealba C, Greenwald M, Brzezicki J, O'Brien K, Soffer B, Polis A, Bird S, Kaur A, Curtis SP; EDGE Study Group..

J Rheumatol. 2007 Feb;34(2):408-20.

PMID:
17304660
16.

Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.

Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C.

Gastroenterology. 2003 Feb;124(2):288-92.

PMID:
12557133
17.

The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis.

Ramey DR, Watson DJ, Yu C, Bolognese JA, Curtis SP, Reicin AS.

Curr Med Res Opin. 2005 May;21(5):715-22.

PMID:
15974563
18.

Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.

Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL.

Lancet. 2010 Jul 17;376(9736):173-9. doi: 10.1016/S0140-6736(10)60673-3. Epub 2010 Jun 16. Erratum in: Lancet. 2011 Jul 16;378(9787):228.

PMID:
20638563
19.

Global gastrointestinal safety profile of etoricoxib and lumiracoxib.

Yuan Y, Hunt RH.

Curr Pharm Des. 2007;13(22):2237-47. Review.

PMID:
17691997
20.

Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.

Moore A, Phillips C, Hunsche E, Pellissier J, Crespi S.

Pharmacoeconomics. 2004;22(10):643-60.

PMID:
15244490

Supplemental Content

Support Center